Brokerages Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) Target Price at $5.77

Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) have been assigned a consensus rating of “Moderate Buy” from the six brokerages that are covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $5.02.

CTMX has been the topic of a number of recent research reports. HC Wainwright reiterated a “neutral” rating on shares of CytomX Therapeutics in a report on Friday, March 7th. StockNews.com raised CytomX Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday. Finally, Wedbush reiterated an “outperform” rating and issued a $5.00 price target on shares of CytomX Therapeutics in a research report on Friday, March 7th.

CytomX Therapeutics Trading Down 7.4 %

CytomX Therapeutics stock opened at $0.62 on Wednesday. The company has a market capitalization of $48.55 million, a PE ratio of 3.65 and a beta of 1.05. The stock has a 50-day moving average price of $0.83 and a two-hundred day moving average price of $1.01. CytomX Therapeutics has a 12 month low of $0.60 and a 12 month high of $5.85.

CytomX Therapeutics (NASDAQ:CTMX) last issued its quarterly earnings data on Thursday, March 6th. The biotechnology company reported $0.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.45. CytomX Therapeutics had a net margin of 10.96% and a negative return on equity of 41.47%. The business had revenue of $38.09 million during the quarter, compared to analyst estimates of $13.53 million. As a group, analysts predict that CytomX Therapeutics will post -0.05 earnings per share for the current fiscal year.

Institutional Trading of CytomX Therapeutics

Institutional investors have recently bought and sold shares of the company. Miller Financial Services LLC bought a new position in shares of CytomX Therapeutics in the 4th quarter worth about $26,000. Traphagen Investment Advisors LLC bought a new stake in CytomX Therapeutics in the fourth quarter worth approximately $31,000. Algert Global LLC acquired a new position in CytomX Therapeutics in the fourth quarter valued at approximately $35,000. Velan Capital Investment Management LP bought a new position in shares of CytomX Therapeutics during the 4th quarter worth approximately $36,000. Finally, US Bancorp DE acquired a new stake in shares of CytomX Therapeutics during the 3rd quarter worth approximately $40,000. Institutional investors own 67.77% of the company’s stock.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.